Avidity Biosciences misses HARBOR endpoint: analysts target RNA stock at USD 63.75

Published on 10/06/2026 at 11:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 3.00 million versus USD 0.67 million consensus. RNA stock was USD 7.84 versus its USD 16.77 high on October 2, 2026.

RNA, US05370A1088, Illustration mit AI erstellt.

Avidity Biosciences (ISIN US05370A1088) faces a major clinical reset after Novartis said on September 8, 2026, that the HARBOR Phase 3 study of del-desiran missed its primary endpoint in myotonic dystrophy type 1. According to Securities.io, the trial did not demonstrate statistically significant improvement over placebo in video hand opening time. MarketBeat reported on September 19, 2026, that 16 analysts carried a consensus Hold rating and an average 12-month target of USD 63.75 for RNA stock.

HARBOR miss changes the clinical case

HARBOR evaluated del-desiran over 54 weeks in 159 participants with myotonic dystrophy type 1. The primary measure, video hand opening time, was designed to assess delayed muscle relaxation, while secondary measures included hand grip strength, daily activities and walking performance.

The result matters because del-desiran was the lead asset from Avidity's antibody oligonucleotide conjugate platform. The company combines antibody targeting with oligonucleotide medicines intended to deliver RNA therapies into muscle cells, according to its Avidity Biosciences homepage.

Revenue beat did not change the risk

Avidity reported second-quarter 2026 revenue of USD 3.00 million against a USD 0.67 million consensus estimate, while its loss was USD 1.18 per share against an expected USD 1.42 loss, according to MarketBeat. Revenue therefore exceeded consensus by USD 2.33 million, but the later Phase 3 outcome shifted attention from near-term financial performance to clinical validation.

The analyst distribution was mixed: MarketBeat listed 11 Hold ratings, three Buy ratings, one Strong Buy and one Sell on September 19, 2026. The USD 63.75 average target sits alongside a USD 25.00 low target and a USD 74.00 high target, showing a wide range of views on the remaining pipeline.

RNA market value after HARBOR

RNA stood at USD 7.84 on Nasdaq on October 2, 2026, against a 52-week range of USD 7.68 to USD 16.77. The market capitalization was USD 134.1 million on the same date, making the clinical outcome central to how the market values Avidity's remaining programs.